{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:12Z","timestamp":1786118892346,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1097\/md.0000000000001928","type":"journal-article","created":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T06:39:52Z","timestamp":1446100792000},"page":"e1928","source":"Crossref","is-referenced-by-count":10,"title":["Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment"],"prefix":"10.1097","volume":"94","author":[{"given":"Meiying","family":"li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruigang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-74-20210226","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer.","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"R2-74-20210226","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1158\/1078-0432.CCR-08-1208","article-title":"Triple-negative breast cancer: risk factors to potential targets.","volume":"14","author":"Schneider","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R3-74-20210226","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2559.2007.02889.x","article-title":"Triple negative tumours: a critical review.","volume":"52","author":"Reis-Filho","year":"2008","journal-title":"Histopathology"},{"key":"R5-74-20210226","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1200\/JCO.2011.38.2010","article-title":"Dissecting the heterogeneity of triple-negative breast cancer.","volume":"30","author":"Metzger-Filho","year":"2012","journal-title":"J Clin Oncol"},{"key":"R6-74-20210226","doi-asserted-by":"crossref","first-page":"vi40","DOI":"10.1093\/annonc\/mds194","article-title":"Adjuvant treatments for triple-negative breast cancers.","volume":"23","author":"Joensuu","year":"2012","journal-title":"Ann Oncol"},{"key":"R7-74-20210226","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","article-title":"Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.","volume":"26","author":"Atchley","year":"2008","journal-title":"J Clin Oncol"},{"key":"R8-74-20210226","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","article-title":"Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.","volume":"17","author":"Gonzalez-Angulo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R9-74-20210226","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/annonc\/mdq461","article-title":"Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience.","volume":"22","author":"Staudacher","year":"2011","journal-title":"Ann Oncol"},{"key":"R10-74-20210226","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ijc.28966","article-title":"Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.","volume":"136","author":"Zhang","year":"2015","journal-title":"Int J Cancer"},{"key":"R11-74-20210226","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10549-014-2876-z","article-title":"The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.","volume":"144","author":"Petrelli","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"R12-74-20210226","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/(SICI)1097-0142(19980101)82:1<134::AID-CNCR16>3.0.CO;2-3","article-title":"Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- andor paclitaxel-containing regimens.","volume":"82","author":"Ray-Coquard","year":"1998","journal-title":"Cancer"},{"key":"R13-74-20210226","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1081\/CNV-120022358","article-title":"Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.","volume":"21","author":"Vassilomanolakis","year":"2003","journal-title":"Cancer Invest"},{"key":"R14-74-20210226","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10549-008-0086-2","article-title":"Pattern of metastatic spread in triple-negative breast cancer.","volume":"115","author":"Dent","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"R15-74-20210226","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.22381","article-title":"Prognostic markers in triple-negative breast cancer.","volume":"109","author":"Rakha","year":"2007","journal-title":"Cancer"},{"key":"R16-74-20210226","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1524-4741.2008.00622.x","article-title":"Impact of triple negative phenotype on breast cancer prognosis.","volume":"14","author":"Kaplan","year":"2008","journal-title":"Breast J"},{"key":"R17-74-20210226","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10549-014-3033-4","article-title":"Platinum-based chemotherapy in triple-negative advanced breast cancer.","volume":"146","author":"Villarreal-Garza","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"R18-74-20210226","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/1097-0142(20011101)92:9<2267::AID-CNCR1572>3.0.CO;2-Q","article-title":"Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.","volume":"92","author":"Zelek","year":"2001","journal-title":"Cancer"},{"key":"R19-74-20210226","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000151630","article-title":"Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes.","volume":"54","author":"Oksuzoglu","year":"2008","journal-title":"Chemotherapy"},{"key":"R20-74-20210226","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000214143","article-title":"Cisplatin plus gemcitabine chemotherapy in taxaneanthracycline-resistant metastatic breast cancer.","volume":"55","author":"Somali","year":"2009","journal-title":"Chemotherapy"},{"key":"R21-74-20210226","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1200\/JCO.2009.24.4244","article-title":"Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.","volume":"28","author":"Sparano","year":"2010","journal-title":"J Clin Oncol"},{"key":"R22-74-20210226","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/sj.onc.1210014","article-title":"BRCA1 dysfunction in sporadic basal-like breast cancer.","volume":"26","author":"Turner","year":"2007","journal-title":"Oncogene"},{"key":"R23-74-20210226","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1541-7786.MCR-05-0192","article-title":"The role of the BRCA1 tumor suppressor in DNA double-strand break repair.","volume":"3","author":"Zhang","year":"2005","journal-title":"Mol Cancer Res"},{"key":"R24-74-20210226","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1172\/JCI30866","article-title":"The p63p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers.","volume":"117","author":"Leong","year":"2007","journal-title":"J Clin Invest"},{"key":"R25-74-20210226","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","article-title":"Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.","volume":"28","author":"Silver","year":"2010","journal-title":"J Clin Oncol"},{"key":"R26-74-20210226","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1200\/JCO.2012.46.2408","article-title":"Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.","volume":"31","author":"Baselga","year":"2013","journal-title":"J Clin Oncol"},{"key":"R27-74-20210226","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1200\/JCO.2014.57.6660","article-title":"TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.","volume":"33","author":"Isakoff","year":"2015","journal-title":"J Clin Oncol"},{"key":"R28-74-20210226","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/annonc\/mds603","article-title":"Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer.","volume":"24","author":"Fan","year":"2013","journal-title":"Ann Oncol"},{"key":"R29-74-20210226","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1023\/A:1008377724931","article-title":"Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines.","volume":"11","author":"Vassilomanolakis","year":"2000","journal-title":"Ann Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000001928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:51:31Z","timestamp":1786035091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201510270-00074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":28,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000001928","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}